## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dario NERI et al.						
Serial I	No.: 09/	194,356	Group Art Unit: 1642			
Filed:	Septeml	per 2, 1999	Examiner: Alana M. Harris			
For: Al	NTIBO:	DIES TO ED-B DOMAIN OF FIBRONECT	IN, THEIR CONSTRUCTION AND			
INFO	RMAT	ION DISCLOSURE STATEMENT UND	ER 37 CFR §§ 1.56, 1.97 and 1.98			
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450						
Sir:						
and 1.9	This information disclosure statement is made in accordance with 37 C.F.R. §§ $1.56$ , $1.97$ and $1.98$ as follows:					
Timin	g and Fo	ees				
	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:					
		within three months of the filing date of a runder § 1.53(d);	national application other than a CPA			
		within three months of the actual filing of application; OR	late of the national phase of a PCT			
		before the mailing of a first substantive off RCE).	ice action (including after filing of an			
	Under specif	37 C.F.R. § 1.97(c), this information disclosied in 37 C.F.R. § 1.97(b), but before the ma	fure statement is filed after the periods ailing date of:			
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte C a notice of allowance under 37 C.F.R. § 1.				

		is acco	empanied by:		
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR		
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).		
$\boxtimes$	Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after to date of the following actions which have not been withdrawn:				
	$\boxtimes$	a final	action under 37 C.F.R. § 1.113;		
		termin	nation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);		
		OR a	notice of allowance under 37 C.F.R. § 1.311;		
	AND	is filed	on or before payment of the issue fee; AND is accompanied by:		
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).		
Stater	nents U	nder 37	C.F.R. 1.97(e)		
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or		
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.		
Cited	Materia	als			
		Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120 ancestor application Serial No, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).			
			es of materials listed but not attached were cited in an international search dated		
		Not re	equired by 37 CFR § 1.98.		
	$\boxtimes$	Copie	es of the materials listed are attached (except for the foregoing).		

Non-English Language References				
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).		
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:		
		X = document of particular relevance when it is taken alone		
		Y = document of particular relevance when it is combined with another such document		
		A = document defining the general state of the art		
		O = non-written disclosure		
		P = intercalated document		
		T = document cited to understand the theory or principle underlying the invention		
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date		
		D = cited in the application		
		L = cited for another reason		
		& = publication of member of same patent family		
		Translation of other relevant information on foreign search report		
Other !	<u>Inform</u>	ation		
Payme	ent of F	ees Due (If Any):		
	The \$	180.00 fee identified above is being paid by Credit Card through EFS-web.		
	Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.			

 $\boxtimes$ The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

/Anthony J. Zelano/ Anthony J. Zelano, Reg. No. 27,969 Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: ELLIS-0003

Date: March 8, 2007

AJZ:hlw

K:\Ellis-3\Information Disclosure Statement 3.8.07.doc

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known		
INFORMATION DISCLOSURE				Application Number	09/194,356	
				Filing Date	September 2, 1999	
STATE	STATEMENT BY APPLICANT			First Named Inventor	Dario NERI et al.	
				Group Art Unit	1642	
(us	se as many sh	eets as ne	cessary)	Examiner Name	Alana M. Harris	
Sheet	1	of	1	Attorney Docket Number	ELLIS-0003	

	វត្តខ្លេងចំពោះទៅចំនៅមុ ស្រាស់មានក្រុងខ្លែងមុំព ស្រាស់ខ្លែងទៅទីស្រាស់	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1	EPSTEIN, Jay S., "FDA Regulation of HIV-Related Tests and Procedures," Aids Testing: A comprehensive Guide to Technical, Medical, Social, Legal, and Management Issues, Eds. Schochetman and George, pp. 52-61, Springer-Verlag, New York.	
	2	KORVER et al., "Measurement of Primary In Vivo IgM- and IgG-Antibody Response to KLH in Humans: Implications of Pre-Immune IgM Binding in Antigen-Specific ELISA," Journal of Immunological Methods, 1984, pp. 241-251, vol. 74.	
i	3	WEIR, C. et al., "An Immunoglobulin G1 Monoclonal Antibody Highly Specific to the Wall of Cryptosporidium Oocysts," Clinical and Diagnostic Laboratory Immunology, Sept. 2000, p. 745-750, Vol. 7, No. 5.	
	4	NOZAWA, Shiro, et al., "HMMC-1: A Humanized Monoclonal Antibody With Therapeutic Potential Against Müllerian Duct-Related Carcinomas," Clinical Cancer Research, October 15, 2004, pp. 7071-7078, vol. 10.	
	5	23 slide, power-point of Dr. Zardi (February 2007).	
	ļ		

1	Examiner	Date	
	Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.